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Background: Resistance towards endocrine therapy is a great concern in breast cancer treatment and may partly
be explained by the activation of compensatory signaling pathways. The aim of the present study was to
investigate if the insulin-like growth factor-1 receptor (IGF1R) signaling pathway was activated or deregulated in
breast cancer patients and to explore if any of the markers were prognostic, with or without adjuvant tamoxifen.
This signaling pathway has been suggested to cause estrogen independent cell growth and thus contribute to
resistance to endocrine treatment in estrogen receptor (ER) positive breast cancer.
Methods: The protein expression of IGF1R, phosphorylated Mammalian Target of Rapamycin (p-mTOR) and
phosphorylated S6 ribosomal protein (p-S6rp) were investigated by immunohistochemistry using tissue microarrays
in two patient cohorts. Cohort I (N = 264) consisted of mainly postmenopausal women with stage II breast cancer
treated with tamoxifen for 2 years irrespective of ER status. Cohort II (N = 206) consisted of mainly medically
untreated, premenopausal patients with node-negative breast cancer. Distant disease-free survival (DDFS) at 5 years
was used as end-point for survival analyses.
Results: We found that lower IGF1R expression was associated with worse prognosis for tamoxifen treated,
postmenopausal women (HR = 0.70, 95% CI = 0.52 – 0.94, p = 0.016). The effect was seen mainly in ER-negative patients
where the prognostic effect was retained after adjustment for other prognostic markers (adjusted HR = 0.49, 95%
CI = 0.29 – 0.82, p = 0.007). Expression of IGF1R was associated with ER positivity (p < 0.001) in the same patient cohort.
Conclusions: Our results support previous studies indicating that IGF1R positivity reflects a well differentiated tumor
with low metastatic capacity. An association between lack of IGF1R expression and worse prognosis was mainly seen in
the ER-negative part of Cohort I. The lack of co-activation of downstream markers (p-mTOR and p-S6rp) in the IGF1R
pathway suggested that the prognostic effect was not due to complete activation of this pathway. Thus, no evidence
could be found for a compensatory function of IGF1R signaling in the investigated cohorts.
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Breast cancer is a common disease in the Western world
and one in eight women gets the diagnosis during her
lifetime. Breast cancer treatment is often successful and
therapy can be targeted based on the expression of bio-
markers such as the estrogen receptor (ER) and human
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initially respond many will develop resistance during
therapy [1]. As no single mechanism can explain all
cases of resistance, the study of alternative/compensa-
tory signaling pathways is important for future treatment
combinations to decrease the risk of adaptive resistance.
Expression of predictive biomarkers in addition to ER
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(IGF1R) is essential for survival of many oncogenic cells
and its important role in cancer is well established [2]. In
normal tissue, activation of IGF1R by its ligands IGF-I and
IGF-II is important for regulation of cell differentiation,
proliferation and metabolism and IGF1R gene transcrip-
tion has been found to be suppressed by functional tumor
suppressor genes such as BRCA1 [3] and p53 [4,5]. It has
also been shown that estrogens and ER can increase
IGF1R signaling [6,7] and IGF1R can in its turn phosphor-
ylate ER through its downstream activator S6K1 leading
to ligand-independent activation of ER [8] (Figure 1). This
crosstalk between IGF1R and ER has led to the proposal
of combined anti-IGF1R and anti-ER therapies to decrease
resistance development in ER-positive breast cancer [9].
Downstream of IGF1R, activation of several substrates
and phosphorylation events in the signaling cascade
(Figure 1) also provides possibilities for combined treat-
ment. Mammalian Target of Rapamycin (mTOR) is part
of the common PI3K/Akt signaling pathway that transfers
proliferative signals from a number of different receptor
tyrosine kinases (RTKs), including IGF1R. Upon stimula-
tion, mTOR induces activation of S6K1 with subsequent
phosphorylation of S6 ribosomal protein (S6rp) resultingFigure 1 Schematic illustration of the IGF1R/mTOR signaling pathway
between the IGF1R signaling pathway and estrogen and the estrogen recein an increase in mRNA translation and cell proliferation.
S6K1 can also be activated by the Ras/MEK/MAPK-cas-
cade, another possible pathway transferring growth pro-
moting signals from IGF1R [10] (Figure 1).
In vitro experiments have shown promising results for
targeting this pathway in combination with endocrine ther-
apy [11,12]. However, clinical studies have yet to prove a
positive effect of IGF1R inhibition in the therapeutic
setting and it is possible that selection of patients ap-
propriate for this type of treatment is needed. Targeting
mTOR together with endocrine therapy in metastatic
breast cancer has provided successful results with pro-
longed progression-free survival in the large BOLERO-
2 study [13] and improved clinical benefit rate, time to
progression and overall survival in the GINECO study
[14]. Combined therapy against mTOR and IGF1R is
currently investigated in clinical trials [15].
Studies of the prognostic role of IGF1R in breast cancer
have so far given discrepant results. A few studies have
found that high expression of the IGF1R protein [16] or
mRNA [17] was associated with shorter survival and
worse prognosis, whereas other studies have found an as-
sociation between longer survival and high IGF1R expres-
sion [18-21]. High levels of phosphorylation of mTOR orresulting in growth and survival of the cell. Examples of cross-talk
ptor (ER) are shown.
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ways and not solely indicative for IGF1R activation. High
mTOR expression has been associated with aggressive dis-
ease and higher risk of recurrence [22,23] and phosphoryl-
ation of mTOR has also been found to increase with
disease progression [24]. In a recent study, high p-mTOR
expression was associated with decreased tamoxifen re-
sponse [25]. S6K1 overexpression has been found in high-
grade breast cancers [23] and when co-expressed with
IGF1R it has been related to poor survival in all breast can-
cer subtypes [16].
The aim of this study was to investigate if IGF1R and its
downstream pathway was activated or deregulated in pri-
mary breast cancer and to explore if any of the markers
were prognostic, with or without adjuvant tamoxifen. We
hypothesized that overexpression of IGF1R, possibly in
combination with over-activation of the downstream
markers mTOR and S6rp, could be associated with worse
prognosis for ER-positive patients treated with tamoxifen.
Two cohorts (one tamoxifen treated and one mainly with-
out systemic treatment) were included in the study to in-
vestigate the predictive and prognostic value of marker
expression. However, the results showed that negative
IGF1R was associated with worse prognosis in one of the
investigated cohorts and no indications of overactivation
of the complete pathway could be found. IGF1R expres-
sion was positively associated with ER expression and our
results suggest that high IGF1R expression is associated
with well differentiated tumors with low metastatic cap-
acity. Whenever applicable in the study, the REMARK




Cohort I consisted of mainly postmenopausal patients who
were all treated with tamoxifen for 2 years irrespective of
ER status. The original, prospective study included 445
patients diagnosed with stage II breast carcinoma in the
South Swedish Health Care Region between 1985 and
1994, and has been described in detail previously [27-31].
In addition to tamoxifen, therapy consisted of either breast
conserving surgery and postoperative radiotherapy or
modified radical mastectomy in combination with radio-
therapy (50 Gy) for patients with lymph node-positive can-
cer. 264 patients, of whom 55 (21%) were premenopausal
and 209 (79%) were postmenopausal, could be evaluated in
the present study. Two of the premenopausal patients re-
ceived adjuvant chemotherapy in addition to tamoxifen.
The median follow-up for distant disease-free survival
(DDFS) was 6.1 years for patients free of distant metastases
and alive at the latest review of the patients’ record.
Cohort II consisted of 237 premenopausal patients
with lymph-node negative breast cancer identified in theSouth Swedish Breast Cancer Region between 1991 and
1994. The original prospective study has been described
previously [32,33]. All patients underwent radical sur-
gery for early breast cancer and 117 of the patients re-
ceived post-operative radiotherapy. 206 patients could be
evaluated for IGF1R in the present study and 28 of these
patients were given adjuvant therapy (19 received chemo-
therapy and 9 received endocrine therapy). Median follow-
up for DDFS was 10.9 years for patients alive and free from
distant metastases at the latest review of the patients’
records.
The original studies, as well as the present follow-up
study, of the two cohorts were approved by the Ethics
committee of Lund University.
Tissue microarray and immunohistochemistry
Tissue microarrays (TMAs) were constructed from paraf-
fin blocks of the primary tumors. Two core biopsies
(1.0 mm in diameter) were punched out from representa-
tive areas of each invasive breast cancer and mounted into
a recipient block using a manual TMA machine (Beecher
Instruments, Sun Prairie, WI, USA). 3–4 μm sections of
the recipient blocks were mounted on three separate
slides and stained with three different antibodies using an
automatic immunohistochemistry machine (Autostainer,
DAKO, Glostrup, Denmark) according to standard proce-
dures. Antigen retrieval for IGF1Rβ was done under pres-
sure in Tris-EDTA buffer (pH = 6). The antibody (#3027,
CellSignaling technology, Boston, MA, USA) was diluted
1:300 and incubated in room temperature for 1 hour. The
antibodies phospho-mTOR (Ser2448, #2976, CellSignaling
technology) and phospho-S6rp (Ser235/236, #4858, Cell-
Signaling technology) were diluted 1:50 and 1:100, re-
spectively. Antigen retrieval for p-mTOR and p-S6rp were
done in Tris-EDTA buffer (pH = 9) and incubation was
performed for 30 minutes in room temperature. Breast
cancer cases with strong positive staining as well as com-
pletely negative staining could be identified with the dilu-
tions stated above.
Biomarker evaluation
All slides (IGF1R, p-mTOR and p-S6rp) were digitized
with the ScanScope XT (Aperio, Vista, CA) by LRI In-
struments (Lund, Sweden) and were evaluated by two
independent scorers (HO and KA). Cytoplasmic staining
was evaluated for all three antibodies and the fraction of
stained cancer cells was scored as 0, 1, 5, 10, 20, 30, 40,
50, 60, 70, 80, 90, 95, 99%. The cytoplasmic staining in-
tensity was evaluated as negative (0), weak (1), moderate
(2) or strong (3). For IGF1R, membrane staining was
evaluated by a system adapted from HER2 staining cri-
teria implemented by Hercep Test™ (DAKO) and scored
as 0 (negative), 1 (weak and incomplete membrane stain-
ing), 2 (weak, circumferential staining in more than 10%
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in more than 10% of the cells). TMA cores with only cancer
in situ or with less than 100 cancer cells were considered
non-evaluable. The highest result of the two core biopsies
was selected if antigen expression was heterogeneous. Dis-
cordant cases were re-examined and a consensus decision
was made. Examples of typical staining with experimental
markers are shown in Figure 2. Evaluation of tumor charac-
teristics and standard markers was done as previously de-
scribed for Cohort I [27-31] and Cohort II [32,33]. Both
cohorts were subdivided into four different subgroups
based on St Gallen criteria [34]: Luminal A-like (ER+,
PgR+, Ki67 low, HER2-), Luminal B-like (ER + and PgR-
and/or Ki67 high and/or HER2+), Triple-negative (ER-,
PgR-, HER2-), and HER2-positive (ER-, PgR-, HER2+).
However, expression of ER and the progesterone receptor
(PgR) were evaluated with cytosol enzyme immunoassay as
previously described [29] and the cut-off for positivity was
necessarily different from the latest St Gallen recommenda-
tions [34].
Statistical analyses
Association between the expression of IGF1R, p-
mTOR and p-S6rp and other prognostic factors was
evaluated using Mann–Whitney-test (binary variables)
and Spearman’s rank correlation (continuous variables). In
Cohort I, 10 patients could not be included in any St Gal-
len subgroup due to PgR positivity and ER negativity and
these patients were excluded from subgroup analyses. In
Cohort II, 19 patients were excluded from the analyses for
the same reason. A stability test including these patients
in the Luminal A or Luminal B-like subgroup (depending
on HER2 and Ki67 expression) did not give divergent re-
sults. Differences in the distribution of experimental
markers between subgroups were investigated with
Kruskal-Wallis equality-of-populations rank test corrected
for ties, follo-wed by pairwise Mann–Whitney tests, which
are reported uncorrected for multiple testing.
DDFS with 5 year follow-up was used as endpoint in
prognostic analyses of the experimental markers. DDFS
was estimated and plotted using the Kaplan-Meier method,
and the log-rank test for trend was used to evaluate the ef-
fect of the investigated factors on survival. Cox propor-
tional hazard regression was used in univariable analyses to
obtain hazard ratios (HR), and for multivariable analyses
including interaction testing. In multivariable analyses, tu-
mor size, node status (only Cohort I), ER expression, Ki67
expression, HER2 status, and menopausal status (Cohort I)
or age (Cohort II), were included. The two cohorts were
independently analyzed and both materials were also sub-
divided into ER-positive and ER-negative patients. Separate
survival analyses including only postmenopausal (N = 209)
and only node-positive patients (N = 178), respectively,
were done in Cohort I. Hazard ratio differences betweenstrata were compared by testing for interaction in the Cox-
model. In Cohort II, survival analyses were repeated with-
out the 28 patients that had received adjuvant endocrine
or chemotherapeutic treatment.
For IGF1R expression, 97% of the non-negative tumors
were classified as 95% - 99% positive cells and thus, no
additional information would be provided by including the
fraction of stained cells into the analyses. Thus, the re-
ported results are based on the intensity of staining only.
p-mTOR and p-S6rp staining were more variable regarding
fraction and an H-score system (intensity x fraction result-
ing in four groups with scores 0–10, 11–100, 101–200 and
201–300) was evaluated for analysis of these markers.
However, limited additional information was obtained by
including fraction into the analyses and the presented re-
sults are based on intensity scoring only if nothing else is
stated.
All statistical calculations were done in STATA (Stata-
Corp/SE 11.2 for Windows. 2011. College Station, TX,
USA).Results
Association between tumor characteristics and IGF1R, p-
mTOR and p-S6rp
The distribution of staining intensities for the different ex-
perimental markers is illustrated in Figure 3. For both co-
horts, the association between IGF1R cytoplasm intensity
and tumor characteristics can be found in Table 1. Data
from IGF1R membrane staining gave comparable results
and can be found in detail in Additional file 1 together
with data from p-mTOR and IGF1R staining. Notable is
that in Cohort I there was very strong evidence of a posi-
tive association between ER/PgR positivity and a high ex-
pression of IGF1R (p < 0.001). High p-S6rp was strongly
associated with hormone receptor positivity (p < 0.001 for
both ER and PgR). For p-mTOR there was very strong evi-
dence for a positive association with Ki67 expression
(p < 0.001), and slight evidence for an association with ER
positivity (p = 0.068). In Cohort II, high p-mTOR expres-
sion was associated with ER positivity (p = 0.014) and
higher age (p = 0.026), whereas it was negatively associated
with Ki67 expression (p = 0.010). p-S6rp expression was
positively associated with Ki67 expression and histological
grade (both p < 0.001), and negatively associated with ER
and PgR expression (both p < 0.001). See Table 1 for IGF1R
cytoplasmic expression and Additional file 1 for IGF1R
membrane expression, p-mTOR and p-S6rp expression.
Between the experimental markers, strong positive as-
sociation was found between IGF1R expression in cyto-
plasm and IGF1R expression in the membrane in both
cohorts (p < 0.001). In Cohort I, moderate evidence for
positive association between IGF1R cytoplasmic staining
and p-mTOR staining could also be found (p = 0.038).
Figure 2 Staining of experimental markers. IGF1R cytoplasm (a and b), IGF1R membrane (c and d), p-mTOR (e and f) and p-S6rp (g and h).
Pictures on the left (a, c, e and g) show score 0 (negative) and pictures on the right show score 3 (strong). Pictures by LRI (Lund, Sweden).
Original magnification 10x (TMA cores) and 40x (insert).
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subgroups
In Cohort I, the subgroups defined in St Gallen Inter-
national Guidelines [34] differed in the expression ofIGF1R (p < 0.001 for both cytoplasmic and membrane
staining; Table 1 and Additional file 1). Pairwise compari-
sons revealed that IGF1R intensity was higher in Luminal
A-like (N = 72) and Luminal B-like (N = 80) subgroups
Figure 3 Distribution of staining intensities for the experimental markers.
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Table 1 Cytoplasmic intensity of IGF1R expression in relation to tumor and patient characteristics for Cohort I
(N = 264) and Cohort II (N = 206)
Cohort I % of patients with different
expression levels
Cohort II % of patients with different
expression levels
N Neg Weak Moderate Strong p-value N Neg Weak Moderate Strong p-value
Total 264 11 32 43 14 206 2 30 58 10
Age
Median age 264 63a 61a 63a 60a 0.34b 206 45a 46a 47a 47a 0.026b
Menopausal status
Pre 55 7 29 45 18 0.15c n/a
Post 209 12 33 43 12
Tumor size
0 – 20 mm 78 8 35 50 8 0.83c 156 3 30 58 10 0.74c
>20 mm 186 13 31 40 16 50 2 28 60 10
Node status
N0 86 12 35 41 13 0.52c n/a
N+ 178 11 30 44 14
NHG
1 – 2 186 8 32 45 15 0.086c 138 1 29 62 9 0.39c
3 75 19 31 39 12 66 6 32 50 12
Missing 3 2
ER
Positive 174 3 29 49 18 <0.001c 139 1 27 63 9 0.32c
Negative 80 29 38 29 5 67 4 34 49 12
Missing 10 0
PgR
Positive 133 2 29 52 17 <0.001c 149 1 28 63 7 0.66c
Negative 121 21 34 33 12 57 5 33 46 16
Missing 10 0
Ki67
Low 162 8 33 43 16 0.095c 125 2 32 59 7 0.33c
High 99 17 29 43 10 61 3 28 52 16
Missing 3 20
HER2
Negative 199 9 32 44 15 0.042c 171 1 29 60 9 0.027c
Positive 33 21 33 39 6 22 14 41 36 9
Missing 32 13
St Gallen subgroupsd
Luminal A-like 72 4 32 46 18 <0.001e 92 0 27 64 9 0.24e
Luminal B-like 80 4 26 51 19 32 3 31 53 13
Triple-negative 42 26 43 26 5 32 3 41 41 16
HER2+ (non-luminal) 18 39 33 22 6 8 25 38 25 13
Missing 52 42
Abbreviations: ER = Estrogen receptor, PgR = Progesterone receptor, HER2 = Human epidermal growth factor receptor 2, NHG = Histological grade according to
Elston and Ellis [35], n/a = Not applicable.
aMedian age in the different groups.
bSpearman’s rank-correlation.
cMann–Whitney test.
dSee (34) for complete definition of St Gallen subgroups.
eKruskal-Wallis test.
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positive (N = 18) subgroups (all p < 0.001 for both cyto-
plasmic and membrane staining). However, no difference
in expression was found between the Luminal A and B-like
groups or between the Triple-negative and HER2-positive
groups (p > 0.4 for all comparisons). Lack of p-mTOR ex-
pression was most common in the Triple-negative sub-
group compared to the other subgroups (p < 0.04). No
difference in expression of p-S6rp could be found. In Co-
hort II, no difference in IGF1R intensity or p-S6rp intensity
could be found between St Gallen subgroups. Expression
of p-mTOR was higher in the Luminal subgroups com-
pared to Triple-negative (both comparisons p < 0.001) and
also higher in HER2-positive compared to the Triple-
negative subgroup (p = 0.010). The group sizes were 92
patients in Luminal A-like, 32 in Luminal B-like, 32 in
Triple-negative and 8 in HER2-positive.
Prognostic value of the experimental markers
In the tamoxifen treated Cohort I, Kaplan-Meier analysis
for IGF1R showed worse prognosis for patients lacking
IGF1R expression (Figure 4a). Cytoplasmic and membrane
staining gave comparable results in all analyses, and
only results from the cytoplasmic staining of IGF1R are
presented in the text (see Tables 2 and 3 for membrane
expression). Cox-regression gave a Hazard ratio (HR) of
0.70 per intensity step (95% CI = 0.52 – 0.94, p = 0.016,
Table 2), but the prognostic value of IGF1R cytoplasmic
expression was not retained in multivariable analyses
among all patients in Cohort I (Table 2a).
When stratifying for ER status (Table 3a, Figure 4b) the
prognostic effect was found in the ER-negative (HR = 0.62,
95% CI = 0.40 – 0.96, p = 0.033) but not in the ER-positive
group (HR = 1.2, 95% CI = 0.76 – 2.0, p = 0.40). The differ-
ence between ER-negative and ER-positive patients was
confirmed in interaction analysis (HR = 2.0 for IGF1R in
ER-positive compared to ER-negative patients, p = 0.038).
Thus, there was moderate evidence that the influence
of IGF1R on prognosis was stronger in the ER-negative
group. The interaction remained after multivariable ad-
justment for tumor size, node status, HER2, Ki67, and
menopausal status (p = 0.054 in interaction analyses).
Multivariable analyses after stratification based on ER sta-
tus also showed that the prognostic value of IGF1R only
remained in the ER-negative subgroup (Table 3a). Analy-
zing only postmenopausal (N = 209) or only node-positive
patients (N = 178) in Cohort I increased the effect of
IGF1R intensity on survival by lowering HR to 0.58 (95%
CI = 0.39 – 0.85, p = 0.006) and 0.61 (HR = 0.61, 95%
CI = 0.43 – 0.87, p = 0.006), respectively. However, the dif-
ference between pre- and post-menopausal as well as
between node-positive and node-negative patients could
not be established in interaction analyses (p = 0.37 and
p = 0.18, respectively). p-mTOR and p-S6rp expressionshowed no significant relation to survival in neither
Kaplan-Meier analyses (see Additional file 2) nor Cox-
regression analyses (Table 2a).
In Cohort II where only 9 patients had received endo-
crine treatment, all women were premenopausal and
node-negative. No significant prognostic value could be
found for IGF1R intensity using neither Kaplan-Meier
analyses nor Cox-regression (Table 2b and Figure 4a).
Excluding the 28 patients in Cohort II that had received
adjuvant systemic therapy did not give divergent results
(data not shown). Of the 206 tumors that could be eval-
uated for IGF1R, 67 samples were ER-negative and 139
were ER-positive but ER-stratification did not provide
any prognostic information for the experimental markers
(Table 3b and Figure 4c). No prognostic value could be
found for p-mTOR and p-S6rp intensity in Cohort II
(Additional file 2; Table 2b), but high p-mTOR fraction
gave moderate evidence for decreased survival (HR = 0.98,
95% CI = 0.97 – 1.0, p = 0.035).
Discussion
Our hypothesis at initiation of the study was that over-
activation of the IGF1R pathway could lead to tamoxifen
resistance through for example ligand independent acti-
vation of ER [12,17,36]. This is in line with biological rea-
soning based on the growth promoting and anti-apoptotic
function of IGF1R. However, our results showed that pa-
tients with negative IGF1R expression had significantly
worse prognosis and that phosphorylation of downstream
markers mTOR and S6rp was not associated to prognosis.
Taken together these results suggest that the hypothesis
can be rejected.
In more detail, we could show that IGF1R negativity
was associated with shorter distant disease-free survival
(DDFS) in a cohort of postmenopausal women with stage
II breast carcinoma. Other studies have also found results
indicating an advantageous effect of high IGF1R or an
association between tamoxifen resistance and low IGF1R
[18-21]. A tamoxifen resistant cell line was found to have
decreased levels of IGF1R, and treatment with IGF1R
inhibiting antibodies had no effect on proliferation and
cell growth [37]. Cell line experiments even suggest that
high IGF1R expression could be used as a marker for
endocrine treatment sensitivity [38]. Our results can be
interpreted as indicative of the same conclusion since
shorter DDFS for patients with low IGF1R expression was
found only in the tamoxifen treated Cohort I. In Cohort
II, consisting of premenopausal women without tamoxifen
treatment, no prognostic value of IGF1R expression could
be found. But it has to be considered that only 5 patients
in Cohort II (compared to 30 patients in Cohort I) were
IGF1R-negative, which might hide a possible effect of
IGF1R expression on survival. No association was found
between the experimental markers with the exception of
Figure 4 Distant disease-free survival (DDFS) for patients based on expression of IGF1R in the cytoplasm. The Kaplan-Meier curves show
a) all patients in Cohort I (N = 264) and Cohort II (N = 206), and patients stratified on ER status for b) Cohort I and c) Cohort II.
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Table 2 Prognostic value of IGF1R cytoplasm intensity in Cohort I (a) and II (b)
a)
Cohort I DDFS univariable DDFS multivariableb
Variable N HR 95% CI p-valuea N HR 95% CI p-value
IGF1R cytoplasm (0–3, linear) 264 0.70 0.52-0.94 0.016 220 0.80 0.58-1.1 0.18
Node status (N + vs N0) 264 1.2 0.71-2.1 0.45 220 1.1 0.57-2.0 0.83
Tumor size (>20 mm vs ≤20 mm) 264 2.0 1.0-3.8 0.037 220 1.7 0.80-3.5 0.17
HER2 (pos vs neg) 232 2.0 1.0-3.8 0.037 220 1.3 0.69-2.7 0.39
ER (pos vs neg) 254 0.38 0.23-0.64 <0.001 220 0.56 0.31-1.0 0.062
Ki67 (>20% vs ≤20%) 261 2.4 1.4-3.9 0.001 220 1.5 0.79-2.7 0.23
Menopausal status (post vs pre) 264 0.32 0.19-0.53 <0.001 220 0.37 0.20-0.68 0.001
IGF1R membrane (0–3, linear) 264 0.58 0.39-0.86 0.007
p-mTOR (0–3, linear) 264 0.94 0.78-1.1 0.54
p-S6rp (0–3, linear) 264 0.97 0.75-1.3 0.84
Age (years, linear) 264 0.97 0.94-0.99 0.003
Histologic grade (3 vs 1–2) 261 2.2 1.3-3.6 0.003
PgR (pos vs neg) 254 0.61 0.37-1.0 0.064
b)
Cohort II DDFS univariable DDFS multivariablec
Variable N HR 95% CI p-valuea N HR 95% CI p-value
IGF1R cytoplasm (0–3, linear) 206 0.87 0.52-1.5 0.61 179 1.0 0.59-1.8 0.91
Age (years, linear) 206 0.91 0.86-0.96 0.001 179 0.92 0.86-0.99 0.02
Tumor size (>20 mm vs ≤20 mm) 206 1.9 0.94-3.8 0.07 179 1.2 0.51-2.7 0.70
HER2 (pos vs neg) 193 6.0 2.9-13 <0.001 179 5.1 2.3-11 <0.001
ER (pos vs neg) 206 0.38 0.20-0.75 0.005 179 0.86 0.38-1.9 0.71
Ki67 (>20% vs ≤20%) 186 2.6 1.3-5.2 0.007 179 1.8 0.75-4.1 0.19
IGF1R membrane (0–3, linear) 206 0.87 0.53-1.4 0.57
p-mTOR (0–3, linear) 205 0.94 0.72-1.2 0.66
p-S6rp (0–3, linear) 206 1.2 0.75-2.1 0.41
Histologic grade (3 vs 1–2) 204 2.7 1.4-5.2 0.004
PgR (pos vs neg) 206 0.32 0.16-0.63 0.001
aP-value for Cox-regression.
bMultivariable analysis adjusted for node positivity, tumor size, HER2, ER, Ki67 and menopausal status.
cMultivariable analysis adjusted for age, tumor size, HER2, ER and Ki67.
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cates that there was no specific activation of the pathway
in these patients. However, the stability of phospho-
epitopes has rightfully been questioned [39] and the risk
that pre-analytic handling of the samples could affect this
expression should be considered. In the present study, no
information regarding treatment of individual samples is
available but all samples have been routinely handled ac-
cording to good laboratory practice in established path-
ology departments.
We found an association between high IGF1R and ER
positivity in Cohort I. Comparison between St Gallen
breast cancer subgroups [34] showed significantly higher
expression of IGF1R in Luminal A and B-like subclassescompared to Triple-negative and HER2-positive classes
in Cohort I. This clearly demonstrates strong positive as-
sociation between IGF1R and ER expression. Other
studies have also found that IGF1R correlates with
“good” prognostic factors such as high ER expression
[17] and it has been suggested that IGF1R expression, in
accordance with ER, reflects a well differentiated tumor
[19,20]. Both in vitro and in vivo studies have shown that
mammary tumors induced by IGF1R have weak meta-
static capacity and that lowered expression of IGF1R
is essential for increased cell motility [40,41]. When
analyzing only node-positive patients in Cohort I we
found the prognostic value of IGF1R expression to be
higher (however not significant in interaction analysis)
Table 3 Prognostic value of IGF1R intensity in ER-negative and ER-positive patients in Cohort I (a) and II (b),
respectively
a)
Cohort I DDFS univariable DDFS multivariablea
N HR 95% CI p-value N HR 95% CI p-value
Cytoplasm All patients 264 0.70 0.52-0.94 0.016 220 0.80 0.57-1.1 0.18
ER+ 174 1.2 0.76-2.0 0.40 152 1.21 0.72-2.0 0.46
ER- 80 0.62 0.40-0.96 0.033 68 0.49 0.29-0.82 0.007
Membrane All patients 264 0.58 0.39-0.86 0.007 220 0.71 0.46-1.1 0.13
ER+ 174 0.89 0.54-1.5 0.63 152 0.91 0.54-1.5 0.72
ER- 80 0.44 0.20-0.97 0.041 68 0.32 0.13-0.79 0.014
b)
Cohort II DDFS univariable DDFS multivariableb
N HR 95% CI p-value N HR 95% CI p-value
Cytoplasm All patients 206 0.87 0.52-1.5 0.61 179 1.0 0.59-1.8 0.91
ER+ 139 1.1 0.48-2.5 0.83 122 1.2 0.53-2.9 0.62
ER- 67 0.81 0.42-1.56 0.53 57 0.71 0.32-1.6 0.39
Membrane All patients 206 0.87 0.53-1.4 0.57 179 1.03 0.57-1.9 0.92
ER+ 139 1.3 0.64-2.5 0.51 122 1.2 0.59-2.5 0.60
ER- 67 0.72 0.34-1.5 0.37 57 0.84 0.31-2.3 0.74
aMultivariable Cox-regression for IGF1R intensity adjusted for node positivity, tumor size, HER2, Ki67, menopausal status and, among all patients, ER status.
bMultivariable Cox-regression for IGF1R intensity adjusted for age, tumor size, HER2, Ki67 and, among all patients, ER status.
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possible association between lymph-node spread and the
prognostic value of IGF1R negativity. In summary, there are
previous studies suggesting that high expression of IGF1R is
indicative of a well differentiated tumor with weak metastatic
capacity. Our results support this notion although further
studies have to be performed for conclusive evidence.
Interestingly, we only found a prognostic value of IGF1R
expression in ER-negative patients in Cohort I. A previous
study has suggested that ER-negative patients are indeed
more sensitive to growth promoting signals from IGF1
since they have constant expression of IGF1R and their
response to IGF1 is thus not under estrogen control [7].
When analyzing IGF1R expression only in the postmeno-
pausal women of Cohort I, the effect on survival was
higher. Together with the rest of the results this suggests
that the prognostic signal in this study comes mainly from
ER-negative, postmenopausal and node-positive patients
and that IGF1R negativity is associated with worse survival
mainly in this subgroup of Cohort I. Higher expression
of IGF1R might not reflect increased activation of the
complete system and we found no evidence of pathway
activation in neither mTOR nor S6rp downstream of
highly expressed IGF1R. Co-activation of several receptor
tyrosine kinases (RTKs) has been found in cell lines and
this could possibly explain why blocking a single RTK
often has marginal effect [42]. Downstream signaling from
IGF1R can be transmitted either by the mTOR or by theMAPK pathway, but since the two pathways converge be-
fore activating S6K [10] it is unlikely that downstream
activation in any of the pathways was correlated with
IGF1R expression. Contradictory to several other stud-
ies [22-24], we found no evidence of a prognostic value
of either p-mTOR or p-S6rp intensity. Only the fraction
of expressed p-mTOR was associated with decreased
survival in Cohort II.
Conclusions
We found that IGF1R expression could be positively as-
sociated with hormone receptor expression in one co-
hort of postmenopausal, tamoxifen treated women. We
also found that lack of IGF1R expression was indicative
of inferior survival in the same cohort, mainly in ER-
negative patients. The underlying mechanisms for these
results need further investigation in order to elucidate
the role of IGF1R in the development of resistance
against endocrine therapy in breast cancer.
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